Regulators give many cancer drugs a fast track to market while requiring drugmakers to do more studies after approval. Researchers have found the follow-up studies frequently come up short.
(Image credit: J.B. Reed /Bloomberg via Getty Images)
Cancer Drugs Approved Quickly Often Fail To Measure Up Later
